CTIS2024-512483-59-00进行中（未招募）1 期
TRACK - Treatment of cardiovascular disease with low dose Rivaroxaban in Advanced CKD. - TRACK_001
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 2,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1. People able to provide informed consent who meet all of the following inclusion criteria, 2. Age =18 years, 3. Kidney failure on haemodialysis or peritoneal dialysis, OR CKD stage 4 or 5 (eGFR =29 mL/min/1.73 m2) not receiving renal replacement therapy, 4. Elevated CV risk, defined by at least one of the following: a. History of CAD or PAD or non-haemorrhagic non-lacunar stroke, OR b. Diabetes mellitus, OR c. Age =65 years.
排除标准
- •1. Mechanical/prosthetic heart valve (does not include bioprosthetic valves that do not require therapeutic anticoagulation), 2. Indication for, or contraindication to, anticoagulant therapy, 3. High bleeding risk including any coagulopathy, 4. Lesion or condition considered to be a significant risk of major bleeding, 5. Major bleeding episode in the 30 days prior to study enrolment, or any active and clinically significant bleeding, 6. Current treatment with P2Y12 inhibitors/adenosine diphosphate (ADP) receptor inhibitors (clopidogrel, prasugrel, ticagrelor, cangrelor) or phosphodiesterase inhibitors (dipyridamole), where the treating physician or patient does not wish to stop these medications, 7. Concurrent treatment with strong inhibitors of combined CYP3A4 and P-glycoprotein; or strong inducers of CYP3A4, 8. Any stroke within 1 month prior to enrolment, 9. Any previous history of a haemorrhagic or lacunar stroke, 10. Severe heart failure with known ejection fraction <30% or NYHA class III or IV symptoms, 11. History of hypersensitivity or known contraindication to rivaroxaban, 12. Uncontrolled hypertension (systolic BP =180 mm Hg or diastolic BP =110 mm Hg) at the time of screening, 13. Haemoglobin <90 g/L, or platelet count <100 x 109/L, 14. Significant liver disease (defined as Child-Pugh Class B or C) or ALT >3 times upper normal limit, 15. Kidney transplant recipients with a functioning allograft, or scheduled for living-donor kidney transplant surgery, 16. All countries except Europe: Pregnancy or intention to become pregnant or breast-feeding; Europe only: Women who are not in a postmenopausal state, where postmenopausal is defined as no menses for 12 months without alternative medical causes, 17. Inability to understand or comply with the requirements of the study.
研究者
相似试验
招募中
3 期
Treatment of cardiovascular disease with low dose Rivaroxaban in Advanced Chronic Kidney diseaseCTRI/2020/06/025708George Institute for Global Health
尚未招募
不适用
Cohort Study on Treatment of Cardiovascular Diseases with Traditional Chinese MedicineCardiovascular DiseasesITMCTR2200005811Tianjin University of Traditional Chinese Medicine
已完成
不适用
Concurrent Treatment of Cardiovascular Disease in Peritoneal Dialysis (PD) patients. Multi-center Randomized Clinical Study with Aldosterone blockade (spironolactone) and Angiotensin Receptor Blocker (ARB) or Angiotensin-Converting-Enzyme Inhibitor (ACEI).End-Stage Renal Disease (ESRD) and Cardio-Vascular Disease (CVD)JPRN-UMIN000000492agoya University160
进行中（未招募）
1 期
Can the heart drug enalapril prevent heart damage in patients with newly diagnosed breast cancer and lymphoma receiving chemotherapy?Prevention of cardiotoxicityMedDRA version: 20.0Level: PTClassification code 10048610Term: CardiotoxicitySystem Organ Class: 10007541 - Cardiac disordersEUCTR2017-001094-16-GBSouth Tees NHS Foundation Trust170
招募中
不适用
A comprehensive intervention for cardiovascular disease prevention in selected primary health care facilities in Capricorn District, South Africa: An effectiveness-implementation studyCardiologyPACTR201906616852062niversity of Limpopo600